NDC 68682-709 – Diltiazem Hydrochloride
Diltiazem Hydrochloride 420 mg/1 · Tablet, Extended Release · Oral
Product NDC68682-709
Product details
- Brand name
- Diltiazem Hydrochloride
- Generic name
- Diltiazem Hydrochloride Extended-Release Tablets
- Labeler
- Oceanside Pharmaceuticals
- Dosage form
- Tablet, Extended Release
- Route
- Oral
- Marketing category
- NDA AUTHORIZED GENERIC · NDA021392
- Marketed since
- February 6, 2014
- Listing expires
- December 31, 2026
- Pharmacologic class
- Calcium Channel Blocker
Active ingredients
- Diltiazem Hydrochloride 420 mg/1
Uses, dosage, side effects and warnings for Diltiazem Hydrochloride →
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 68682-709-30 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68682-709-30) | Feb 6, 2014 |
| 68682-709-90 | 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (68682-709-90) | Feb 6, 2014 |
Other Diltiazem Hydrochloride products
- 69097-997 Diltiazem Hydrochloride 420 mg/1 · Tablet, Extended Release · Cipla USA, Inc.
- 69097-993 Diltiazem Hydrochloride 180 mg/1 · Tablet, Extended Release · Cipla USA, Inc.
- 69097-996 Diltiazem Hydrochloride 360 mg/1 · Tablet, Extended Release · Cipla USA, Inc.
- 69097-994 Diltiazem Hydrochloride 240 mg/1 · Tablet, Extended Release · Cipla USA, Inc.
- 69097-995 Diltiazem Hydrochloride 300 mg/1 · Tablet, Extended Release · Cipla USA, Inc.
- 69097-992 Diltiazem Hydrochloride 120 mg/1 · Tablet, Extended Release · Cipla USA, Inc.
- 68682-705 Diltiazem Hydrochloride 180 mg/1 · Tablet, Extended Release · Oceanside Pharmaceuticals
- 68682-704 Diltiazem Hydrochloride 120 mg/1 · Tablet, Extended Release · Oceanside Pharmaceuticals
- 68682-708 Diltiazem Hydrochloride 360 mg/1 · Tablet, Extended Release · Oceanside Pharmaceuticals
- 68682-706 Diltiazem Hydrochloride 240 mg/1 · Tablet, Extended Release · Oceanside Pharmaceuticals
- 68682-707 Diltiazem Hydrochloride 300 mg/1 · Tablet, Extended Release · Oceanside Pharmaceuticals
- 50228-498 Diltiazem Hydrochloride 300 mg/1 · Tablet, Extended Release · ScieGen Pharmaceuticals, Inc.